{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Escitalopram+Oral+Capsules", "query": { "intervention": "Escitalopram Oral Capsules" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Escitalopram+Oral+Capsules&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T09:49:14.074Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01473381", "title": "Safety and Efficacy of Vilazodone in Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Vilazodone", "type": "DRUG" }, { "name": "Placebo to citalopram", "type": "DRUG" }, { "name": "Placebo to vilazodone", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1162, "start_date": "2011-12", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473381" }, { "nct_id": "NCT01111539", "title": "Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder (MDD)" ], "interventions": [ { "name": "Escitalopram", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Blinded capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 211, "start_date": "2010-07-13", "completion_date": "2011-09-20", "has_results": true, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 24, "location_summary": "Cerritos, California • Costa Mesa, California • Irvine, California + 21 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111539" }, { "nct_id": "NCT01369095", "title": "Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depression" ], "interventions": [ { "name": "Duloxetine", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" }, { "name": "BMS-820836 Placebo", "type": "DRUG" }, { "name": "BMS-820836", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 976, "start_date": "2011-07", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chino", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01369095" }, { "nct_id": "NCT02178696", "title": "Predictors of Antidepressant Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depression" ], "interventions": [ { "name": "Placebo, identified as placebo to participants", "type": "OTHER" }, { "name": "Celexa or other antidepressant as clinically indicated", "type": "DRUG" }, { "name": "Placebo, identifed to participants as \"Active medication\"", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 44, "start_date": "2011-01", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178696" }, { "nct_id": "NCT00420004", "title": "A Study for Participants With Major Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "LY2216684", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 469, "start_date": "2006-12", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2018-04-27", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 4, "location_summary": "Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Prairie Village", "state": "Kansas" }, { "city": "Allentown", "state": "Pennsylvania" }, { "city": "Media", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420004" }, { "nct_id": "NCT04965272", "title": "A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "Cariprazine 0.75 mg/day", "type": "DRUG" }, { "name": "Cariprazine 1.5 mg/day", "type": "DRUG" }, { "name": "Cariprazine 3.0 mg/day", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2021-08-18", "completion_date": "2021-08-24", "has_results": false, "last_update_posted_date": "2022-04-12", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 36, "location_summary": "Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Colton", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04965272" }, { "nct_id": "NCT00481325", "title": "Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "pexacerfont", "type": "DRUG" }, { "name": "escitalopram", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 260, "start_date": "2007-07", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 51, "location_summary": "Mesa, Arizona • Burbank, California • Costa Mesa, California + 42 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481325" }, { "nct_id": "NCT03538691", "title": "A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Antidepressant therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1149, "start_date": "2018-07-13", "completion_date": "2022-07-29", "has_results": true, "last_update_posted_date": "2023-10-12", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538691" }, { "nct_id": "NCT01111565", "title": "Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder (MDD)" ], "interventions": [ { "name": "Escitalopram", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 137, "start_date": "2010-10-04", "completion_date": "2011-09-01", "has_results": true, "last_update_posted_date": "2021-12-21", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 15, "location_summary": "Tucson, Arizona • Chino, California • Riverside, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chino", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Hamden", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111565" }, { "nct_id": "NCT01715805", "title": "Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Cariprazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Antidepressant Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1022, "start_date": "2012-11-15", "completion_date": "2016-06-24", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-09-28T09:49:14.074Z", "location_count": 83, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01715805" } ] }